Patents by Inventor Benoít Van den Eynde
Benoít Van den Eynde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230165836Abstract: The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.Type: ApplicationFiled: April 21, 2021Publication date: June 1, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Jingjing ZHU
-
Publication number: 20230149360Abstract: The present invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists in the prevention and/or treatment of spleen disorders, in particular splenomegaly. The inventors showed that clonidine, guanabenz and romifidine efficiently reduced the spleen weight of animal models with cancer-induced splenomegaly, immunization-induced splenomegaly or splenomegaly induced by myelofibrosis.Type: ApplicationFiled: April 21, 2021Publication date: May 18, 2023Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Jingjing ZHU
-
Publication number: 20210353749Abstract: Guanabenz for use with an immunotherapy in the treatment of a cancer or of an infectious disease. In particular, guanabenz is used as an adjuvant for an immunotherapy, such as a cancer immunotherapy or a vaccination. More specifically, guanabenz for use with an adoptive cell therapy, with a therapeutic vaccine, with a checkpoint inhibitor therapy or with a T-cell agonist therapy in the treatment of a cancer. Also, guanabenz for use with a vaccination in the prophylactic and/or therapeutic treatment of an infectious disease.Type: ApplicationFiled: October 23, 2019Publication date: November 18, 2021Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Jingjing ZHU
-
Publication number: 20210244814Abstract: A combination including metformin and cyclophosphamide for use with an immunotherapy in the treatment of a solid cancer. In particular, the combination including metformin and cyclophosphamide is used as an adjuvant for an immunotherapy. More specifically, a combination including metformin and cyclophosphamide for use with an adoptive cell therapy, with a therapeutic vaccine, with a checkpoint inhibitor therapy or with a T-cell agonist therapy, preferably with an adoptive cell therapy or a checkpoint inhibitor therapy, in the treatment of a solid cancer.Type: ApplicationFiled: April 25, 2019Publication date: August 12, 2021Applicant: UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Benoît VAN DEN EYNDE, Veronica FINISGUERRA
-
Patent number: 9410139Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.Type: GrantFiled: September 12, 2008Date of Patent: August 9, 2016Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LUDWIG INSTITUT FOR CANCER RESEARCH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoît Van Den Eynde, Sandra Morel, Cécile Bauche
-
Publication number: 20140227323Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.Type: ApplicationFiled: October 25, 2013Publication date: August 14, 2014Applicants: Ludwig Institute for Cancer, Institut PasteurInventors: Gilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
-
Patent number: 8143011Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: July 13, 2011Date of Patent: March 27, 2012Assignee: Ludwig Institute for Cancer ResearchInventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie, Nathalie Vigneron
-
Publication number: 20110305722Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: July 13, 2011Publication date: December 15, 2011Inventors: Wenbin MA, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
-
Publication number: 20110159017Abstract: The unexpected expression of tryptophan 2,3-dioxygenase (TDO2) in cancer cells and tumors has been established. Methods for diagnosing cancer based on the expression of TDO2 are provided, as are methods for treating cancer and inhibiting the growth of cancer cells by inhibiting TDO2, as well as pharmaceutical compositions.Type: ApplicationFiled: April 10, 2009Publication date: June 30, 2011Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Benoit Van Den Eynde, Luc Pilotte, Etienne De Plaen
-
Publication number: 20110112282Abstract: Compounds of formula (I), and pharmaceutically acceptable salts thereof, in which each compound is adapted to occupy the binding site of human IDO, which comprises a large hydrophobic pocket A and a second, proximal hydrophobic pocket B, the compound comprising at least one of the following elements: (i) a large hydrophobic fragment to substantially fill pocket A in the binding site of human IDO; (ii) an atom that can coordinate to the heme iron of human IDO, (iii) a positively charged group that can form a salt-bridge with the heme 7-propionate of the human IDO; (iv) a negatively charged group that can form a salt-bridge with Arg231 of the human IDO; (v) a hydrophobic group that can form van der Waals interactions with pocket B; and (vi) one or more substituents that can hydrogen bond to Ser167 and to Gly262, and as IDO inhibitors and their therapeutic use, eg in the treatment of cancer.Type: ApplicationFiled: April 15, 2009Publication date: May 12, 2011Inventors: Ute Roehrig, Loay Awad, Olivier Michelin, Benoit Van Den Eynde, Luc Pilotte, Vincent Stroobant, Pierre Larrieu
-
Patent number: 7923534Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: March 17, 1997Date of Patent: April 12, 2011Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon, Pierre Van Der Bruggen, Benoit Van Den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari
-
Publication number: 20100310594Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.Type: ApplicationFiled: March 25, 2010Publication date: December 9, 2010Applicants: Institut Pasteur, a corporation of France, Ludwig Institute for Cancer, a corporation of New YorkInventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
-
Publication number: 20100273671Abstract: Methods for the determination and the classification of a rheumatic condition in a synovial sample of a subject afflicted with a rheumatic condition are disclosed. Methods include the steps of determining in the level of expression of at least 20 genes or gene fragments in the synovial sample and identifying whether the level of expression of the genes in the sample correlates with the presence of a rheumatic condition. Kits are also described for the determination and the classification of rheumatic conditions which contain a low density microarray having probes suitable for hybridizing with at least 20 genes or gene fragments. On the basis of the hybridization results, the rheumatic condition is determined.Type: ApplicationFiled: February 29, 2008Publication date: October 28, 2010Applicants: Universite Catholique de Louvain, Cliniques Universitaires Saint-LucInventors: Bernard Lauwerys, Benoit Van Den Eynde, Frédéric Houssiau, Ilse Gutierrez-Roelens
-
Publication number: 20100009437Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.Type: ApplicationFiled: January 12, 2009Publication date: January 14, 2010Inventors: Beatrice Gaugler, Benoit Van den Eynde, Pierre van der Bruggen, Thierry Boon-Falleur
-
Publication number: 20090233315Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: ApplicationFiled: May 8, 2009Publication date: September 17, 2009Inventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
-
Patent number: 7572885Abstract: The invention relates to new members of the GAGE family referred to as GAGE-7B and GAGE-8. There are differences between these two molecules and the previously described members of the GAGE family on the genomic DNA, complementary DNA, and amino acid level.Type: GrantFiled: October 16, 2002Date of Patent: August 11, 2009Assignee: Ludwig Institute For Cancer ResearchInventors: Olivier De Backer, Benoit Van den Eynde, Thierry Boon-Falleur
-
Patent number: 7547517Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.Type: GrantFiled: September 26, 2003Date of Patent: June 16, 2009Assignee: Ludwig Institute for Cancer ResearchInventors: Wenbin Ma, Benoit Van Den Eynde, Thierry Boon-Falleur, Catherine Germeau, Pierre Coulie
-
Publication number: 20090117143Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.Type: ApplicationFiled: September 12, 2008Publication date: May 7, 2009Inventors: Gilles Dadaglio, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecile Bauche
-
Patent number: 7495074Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.Type: GrantFiled: October 17, 2005Date of Patent: February 24, 2009Assignee: Ludwig Institute for Cancer ResearchInventors: Béatrice Guagler, Benoit Van den Eynde, Pierre van den Bruggen, Thierry Boon-Falleur
-
Patent number: RE40089Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.Type: GrantFiled: January 24, 1996Date of Patent: February 19, 2008Assignee: Ludwig Institute for Cancer ResearchInventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari